tiprankstipranks
Advertisement

VEA - ETF AI Analysis

Compare

Top Page

VEA

Vanguard FTSE Developed Markets ETF (VEA)

Rating:57Neutral
Price Target:
VEA, the Vanguard FTSE Developed Markets ETF, earns a solid overall rating largely because it holds strong, globally diversified companies like HSBC, Novartis, and AstraZeneca, which show healthy financial performance, positive earnings outlooks, and reasonable valuations. Healthcare leaders such as Roche and Nestlé add stability through robust cash flow and long-term growth potential, while energy exposure via Shell introduces some risk from revenue and cash flow challenges. The main risk factor is the fund’s meaningful concentration in large financial and healthcare names, which could make performance more sensitive to those sectors’ cycles.
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year, showing solid momentum in developed markets outside the U.S.
Low Expense Ratio
The fund’s very low ongoing fee means more of the investment return stays in investors’ pockets over time.
Broad Country and Sector Diversification
Holdings spread across many countries and industries help reduce the impact of problems in any single market or sector.
Negative Factors
Heavy Exposure to a Few Countries
A large share of assets is concentrated in markets like Japan, the UK, the U.S., and South Korea, which can increase sensitivity to economic or political issues in those regions.
Top Holdings Tilted Toward Technology and Financials
Several of the largest positions are in technology and financial companies, which can make the fund more affected by swings in those sectors.
Some Mixed Performance Among Top Holdings
While many leading positions have shown strong or steady gains, a few have been weaker, which can slightly drag on overall results.

VEA vs. SPDR S&P 500 ETF (SPY)

VEA Summary

Vanguard FTSE Developed Markets ETF (VEA) is a fund that tracks the FTSE Developed All Cap ex US Index, giving you broad exposure to stocks in developed countries outside the United States, such as Japan, the UK, and Europe. It owns many well-known companies, including Samsung Electronics and Nestlé, across sectors like finance, technology, and industrials. Investors might choose VEA to add international diversification to a U.S.-heavy portfolio and seek long-term growth from established global markets. A key risk is that its value can rise or fall with overseas stock markets and currency movements.
How much will it cost me?The Vanguard FTSE Developed Markets ETF (VEA) has an expense ratio of 0.03%, meaning you’ll pay $0.30 per year for every $1,000 invested. This is much lower than average because it’s a passively managed fund that tracks an index, keeping costs minimal.
What would affect this ETF?The Vanguard FTSE Developed Markets ETF (VEA) could benefit from economic growth in developed markets outside North America, particularly if sectors like financials, technology, and healthcare continue to perform well. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions like Europe and Asia could negatively impact its holdings and overall performance.

VEA Top 10 Holdings

VEA’s story is all about broad developed-markets exposure with a clear tilt overseas, and a few big names setting the tone. ASML has been the star of the show, with its rising share price giving the fund a strong tech tailwind from Europe. On the financial side, HSBC and Royal Bank of Canada have been steadily pulling their weight, while energy giant Shell has been more of a mixed bag lately. In health care, Novartis is holding firm, but Roche and AstraZeneca are losing a bit of steam, slightly dragging on overall performance.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Samsung Electronics3.12%$10.02B₩10.00T>230.73%
SK hynix Inc.2.98%$9.57B₩10.00T>612.06%
ASML Holding NV2.33%$7.47B€607.20B155.85%
76
Outperform
HSBC Holdings0.99%$3.17B£264.80B58.91%
80
Outperform
Novartis AG0.89%$2.85BCHF228.82B36.49%
80
Outperform
Royal Bank Of Canada0.88%$2.83B$294.22B57.90%
75
Outperform
Roche Holding AG0.88%$2.83B$324.59B28.18%
73
Outperform
AstraZeneca0.85%$2.74B$262.40B16.34%
80
Outperform
Nestlé SA0.80%$2.58BCHF221.65B6.80%
71
Outperform
Siemens0.72%$2.31B€206.76B16.26%
74
Outperform

VEA Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price
Price Trends
50DMA
70.56
Negative
100DMA
68.39
Positive
200DMA
65.42
Positive
Market Momentum
MACD
-0.16
Positive
RSI
46.21
Neutral
STOCH
59.36
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VEA, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 70.53, equal to the 50-day MA of 70.56, and equal to the 200-day MA of 65.42, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 46.21 is Neutral, neither overbought nor oversold. The STOCH value of 59.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VEA.

VEA Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$228.68B0.03%
57
Neutral
$65.87B0.03%
61
Neutral
$39.87B0.03%
60
Neutral
$31.32B0.04%
66
Neutral
$17.90B0.23%
65
Neutral
$17.16B0.18%
65
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VEA
Vanguard FTSE Developed Markets ETF
69.78
13.39
23.75%
SCHF
Schwab International Equity ETF
SPDW
SPDR Portfolio Developed World ex-US ETF
IDEV
iShares Core MSCI International Developed Markets ETF
AVDE
Avantis International Equity ETF
DFAI
Dimensional International Core Equity Market ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement